Sign in Subscribe
Cancer

Amifostine Enhances Anti-Cancer Effects of Paclitaxel in Endometrial Cancer

Strategic Insights

— 1 min read

In a groundbreaking study, researchers from the University of New Mexico have discovered that amifostine, a radioprotective agent, significantly enhances the anti-cancer effects of paclitaxel in endometrial cancer cells. The study, published in the International Journal of Oncology, reveals that the synergistic effect between amifostine and paclitaxel is dependent on the status of the TP53 gene. This finding provides a rationale for a clinical trial of combined paclitaxel and amifostine in endometrial cancer patients whose tumors harbor TP53 mutations.

Key Takeaways:

  • The study, conducted by W. Luo and colleagues from the University of New Mexico, found that amifostine significantly enhances the anti-cancer effects of paclitaxel in endometrial cancer cells.
  • The synergistic effect between amifostine and paclitaxel is TP53 status-dependent, with tumors harboring TP53 mutations showing increased sensitivity to the therapeutic effect of paclitaxel and amifostine.
  • Amifostine promotes entry into the G2-M phase through regulation of cyclin-dependent kinase-1 activity in cells with dysfunctional p53, thereby enhancing cancer cell sensitivity to paclitaxel.
  • The study's findings provide a rationale for a clinical trial of combined paclitaxel and amifostine in endometrial cancer patients whose tumors harbor TP53 mutations.
  • The study was published in the International Journal of Oncology (Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent. International Journal of Oncology, 2010;37(5):1187-94).

Statistics:

  • 37.5% rate of TP53 mutations in endometrial cancer tumors (source: cited study)
  • 94% increase in therapeutic response to paclitaxel and amifostine in tumors with nonsense TP53 mutation compared to wild-type TP53 tumors (source: cited study)
  • 5,000 new cases of endometrial cancer diagnosed annually in the United States (source: American Cancer Society)

Sources:

  • International Journal of Oncology (Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent. International Journal of Oncology, 2010;37(5):1187-94)
  • Gene Therapy Weekly (2010)
  • NewsRx.com (2010)

Read more